Adaptimmune stock plunges after announcing Nasdaq delisting plans
SOLANA BEACH, Calif. - Artelo Biosciences, Inc. (NASDAQ:ARTL), currently trading at $5.85 with a market capitalization of $11.82 million, announced Monday it has commenced an underwritten public offering of common stock and/or pre-funded warrants. The clinical-stage pharmaceutical company, which according to InvestingPro data holds more cash than debt on its balance sheet, stated that all securities in the offering will be offered by the company.
R.F. Lafferty & Co., Inc. is serving as the sole book-running manager for the offering, according to the company’s press release statement. The offering is subject to market conditions, with no assurance provided regarding its completion timeline or final terms.
The securities are being offered pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission and declared effective on July 14, 2023.
Artelo Biosciences focuses on developing treatments that modulate lipid-signaling pathways for people with cancer, pain, dermatologic, or neurological conditions. The company’s pipeline targets unmet needs in areas including anorexia, anxiety, and inflammation. While analysts have set an ambitious target price of $18, InvestingPro subscribers can access detailed financial health metrics and 5 additional ProTips to make informed investment decisions.
The company did not disclose the intended use of proceeds from the offering in its announcement. The offering will be made only through a prospectus supplement and accompanying prospectus, which will be filed with the SEC.
Artelo Biosciences noted that the announcement does not constitute an offer to sell or solicitation of an offer to buy securities, and no sales will occur in jurisdictions where such offers would be unlawful prior to registration or qualification under securities laws.
In other recent news, Artelo Biosciences, Inc. has reported interim data from its Phase 2 Cancer Appetite Recovery Study (CAReS), revealing that patients treated with ART27.13 experienced notable improvements in weight, lean body mass, and physical activity. This data was presented at the 8th Cancer Cachexia Society Conference, where it was highlighted that patients receiving the highest dose of ART27.13 achieved an average 6% weight gain over 12 weeks. Additionally, Artelo announced new preclinical data showing that its proprietary CBD:tetramethylpyrazine cocrystal, ART12.11, demonstrated superior effectiveness in treating stress-induced depression and anxiety compared to CBD alone. The study, conducted with Western Ontario University, was published in Progress in Neuro-Psychopharmacology and Biological Psychiatry. Artelo Biosciences has also closed a $3 million public offering of common stock, selling 640,924 shares and pre-funded warrants to purchase additional shares. Following this capital raise, D. Boral Capital downgraded Artelo’s stock rating from Buy to Hold, citing uncertainty after a "confusing crypto-related initiative." These developments reflect the company’s ongoing efforts in advancing its pharmaceutical initiatives and managing its financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.